Reference pricing systems in Europe: characteristics and consequences

Journal Title: Generics and Biosimilars Initiative Journal - Year 2012, Vol 1, Issue 3

Abstract

Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview of the different characteristics of the different reference pricing systems in Europe. Additionally, the impact of reference pricing on price competition, generic medicine use, pharmaceutical expenditure and health outcome will be discussed. Methods: Studies relevant for this article were found by means of a literature review. A survey was carried out to document the current status of reference pricing systems in Europe. Survey data were collected from member associations of the European Generic medicines Association in the context of their 2011 survey of European drug retail markets. Results: Many European governments have introduced reference pricing systems. Reference pricing systems reduce medicine prices but not always below the reference price, increase the use of medicines priced at or below the reference price, generate savings in pharmaceutical expenditure that tend to be limited to the short term, and do not seem to adversely affect health outcomes. Conclusion: Reference pricing is a popular policy for governments to contain pharmaceutical expenditures and seems to be effective in the different European countries.

Authors and Affiliations

Pieter Dylst, Steven Simoens, Arnold G Vulto

Keywords

Related Articles

EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates

The European Organisation for Research and Treatment of Cancer (EORTC) has updated its 2006 guideline on the use of granulocyte colony-stimulating factor (G-CSF) for the prevention of febrile neutropenia (FN), a sometime...

Reference pricing systems in Europe: characteristics and consequences

Introduction: A reference pricing system is a system that establishes a common reimbursement level or reference price for a group of interchangeable medicines, i.e. the reference group. This article provides an overview...

WHO leadership in public safety on biosimilars to be commended

As a practicing endocrinologist and Chairman of the Alliance for Safe Biologic Medicines, I am writing to commend the World Health Organization for its attention to and upcoming action on the important issue of non-propr...

Health authority perspective on biosimilars

Dr Brian Godman reviews Mr Gustaf Befrits’ paper on the case for biosimilars from a payer’s perspective. Biosimilars are increasingly important to payers with growing resource pressures. However, key issues need addressi...

Safety and toxicity of biosimilars—EU versus US regulation

Background: As patents for biological drugs begin to expire, the need for scientific guidance on biosimilar drugs grows increasingly important. The European Medicines Agency provided the first guidelines to cover the app...

Download PDF file
  • EP ID EP355644
  • DOI 10.5639/gabij.2012.0103-4.028
  • Views 123
  • Downloads 0

How To Cite

Pieter Dylst, Steven Simoens, Arnold G Vulto (2012). Reference pricing systems in Europe: characteristics and consequences. Generics and Biosimilars Initiative Journal, 1(3), 127-131. https://europub.co.uk/articles/-A-355644